Panoramica dell'azienda
Apellis Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapeutic compounds designed to address diseases characterized by significant unmet medical needs. The company functions within the Healthcare sector, specifically in the Biotechnology industry, a domain focused on creating innovative biological treatments rather than mass-market pharmaceuticals. Its operational scale is reflected in a market capitalization of $5.20B, an annual revenue of $1.00B, and an workforce comprising 733 employees. These valuation and revenue metrics position Apellis as a mid-to-large-cap biotechnology firm with substantial resources allocated toward R&D and commercial expansion, distinguishing it from smaller clinical-stage peers while indicating a mature revenue generation phase in its pipeline execution.
Salute finanziaria
The company reported a trailing twelve-month revenue of $1.00B and net income of $22.39M, with EBITDA standing at $56.98M, highlighting a significant divergence between top-line sales and bottom-line profitability. The gap between the $1.00B revenue and the $22.39M net income reveals a cost structure where operating expenses, likely dominated by research and development and commercialization costs, consume the majority of generated cash flow before reaching net profit. Free cash flow is reported at $-15,464,500, indicating a net cash outflow that suggests the company is currently investing heavily in its operations or pipeline, which limits immediate financial flexibility but is typical for growth-stage biotech firms. Margin analysis shows a gross margin of 60.3%, reflecting the high value of its biologic products, contrasted sharply by an operating margin of -25.6% and a profit margin of 2.2%, which underscores the heavy overhead required to sustain its commercial and research activities. Regarding liquidity and leverage, the company holds $467.79M in cash against $474.36M in debt, resulting in a debt-to-equity ratio of 128.15, which characterizes the balance sheet as highly leveraged with debt nearly equal to liquid assets. Despite the high leverage, the current ratio stands at 3.14, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is 7.5% and return on assets is 3.5%, metrics that suggest management is generating moderate returns on the capital deployed, though the low ROA is consistent with an asset-heavy or high-investment biotechnology model.
Valutazione del valore
The valuation metrics display a stark contrast between historical and forward-looking expectations, with a trailing P/E ratio of 225.83 and a forward P/E of -166.43. The negative forward P/E implies that the market anticipates continued negative earnings or significant investment outflows in the coming year, causing the price-to-earnings multiple to lose its traditional interpretive value for growth projection. The price-to-book ratio is 13.91, indicating that the market values the company at a significant premium over its net asset book value, a common phenomenon for firms with intangible assets like intellectual property and pipeline potential. Alternative valuation measures such as the price-to-sales ratio of 5.18 and an EV/EBITDA of 91.30 further suggest that investors are pricing the stock based on revenue growth and asset quality rather than current profitability. The 52-week price range spans from a low of $16.10 to a high of $40.76, providing a clear context for price volatility and historical trading bounds. Without a specific current share price provided in the available facts to calculate the exact percentage relative to the range, the valuation must be assessed against these fixed historical bounds of $16.10 and $40.76 which define the investment risk profile. The beta value is -0.20, an unusual metric for equities that indicates the stock price moves inversely to the broader market or exhibits volatility patterns distinct from the standard positive correlation seen in most large-cap stocks.
Growth & Income
The company's financial trajectory shows a revenue growth year-over-year of -5.9%, while earnings growth is marked as N/A due to the relatively small net income figure compared to revenue. The negative revenue growth suggests a contraction in sales or market penetration, which is the primary driver for the current earnings situation rather than a decoupling of earnings from revenue. Since the company does not pay a dividend, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where earnings are reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This absence of dividend payouts combined with negative revenue growth points to a growth-and-reinvestment profile where the company sacrifices current income distribution to fund its long-term therapeutic pipeline.